<DOC>
	<DOCNO>NCT00002146</DOCNO>
	<brief_summary>To determine whether acute ionized hypomagnesemia hypocalcemia immediately follow foscarnet infusion lessen eliminate prior infusion magnesium sulfate . To determine whether reduction ionized magnesium , ionized calcium , parathyroid hormone level follow foscarnet infusion lessen preinfusion magnesium sulfate . To evaluate safety intravenous magnesium sulfate prior foscarnet infusion monitor blood pressure , heart rate , heart rhythm . To characterize effect magnesium sulfate foscarnet blood level urinary excretion calcium , magnesium , phosphate , foscarnet .</brief_summary>
	<brief_title>Safety Efficacy Intravenous Magnesium Sulfate Modulating Changes Symptoms Divalent Cation Levels Associated With Foscavir Therapy : A Phase IV Randomized , Double-Blind , Placebo-Controlled , Cross-Over , Pilot Study</brief_title>
	<detailed_description>Patients randomize one four treatment group . Intravenous foscarnet administer 4 day . Patients receive one three dos magnesium sulfate placebo normal saline accord one four schedule . Sequence dos differ group .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<mesh_term>Hypocalcemia</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>Inclusion Criteria Patients must : AIDS CDC criterion . Documented CMV disease . Tolerance foscarnet dose 90 mg/kg bid . Normal serum calcium , serum creatinine , serum phosphate . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Known allergy Foscarnet . In extremis incapacitate underlying illness ( e.g. , comatose tracheally intubate ) . Volume depletion . Concurrent Medication : Excluded : Nephrotoxic drug IV pentamidine , amphotericin B , aminoglycosides , cisplatin . Other investigational drug affect metabolic balance , human growth hormone . Oral parenteral magnesium calcium supplementation . Patients follow prior condition exclude : History heart block .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 1997</verification_date>
	<keyword>Infusions , Intravenous</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Magnesium Sulfate</keyword>
	<keyword>Magnesium Deficiency</keyword>
	<keyword>Hypocalcemia</keyword>
</DOC>